PDCD1 and hepatocellular carcinoma: The confirmatory phase III keynote 240 clinical trial did not meet statistical significance for the overall survival of pembrolizumab versus placebo, raising the question if single agent PD-1 inhibition is sufficient as a target in HCC [10].